Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 1967K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sumimoto, H. Articles by Kawakami, Y. Search for Related Content PubMed PubMed Citation Articles by Sumimoto, H. Articles by Kawakami, Y. Related Collections Related Article Social Bookmarking                            What's this?

Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan

CORRESPONDENCE Yutaka Kawakami: yutakawa{at}sc.itc.keio.ac.jp

The mitogen-activated protein kinase (MAPK) pathway is frequently activated in human cancers, leading to malignant phenotypes such as autonomous cellular proliferation. Here, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAF^V600E). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF^V600E decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation. The suppressive activity of the culture supernatants from the melanoma cells on the production of inflammatory cytokines IL-12 and tumor necrosis factor by dendritic cells upon lipopolysaccharide stimulation was markedly reduced after transduction with BRAF^V600E RNAi, comparable to the effects observed with STAT3 RNAi transduction. No additive or synergistic effects were observed by the simultaneous transduction of RNAi for both BRAF^V600E and STAT3. Furthermore, specific DNA binding and transcriptional activity of STAT3 were not affected by down-regulation of the MAPK signaling with the BRAF RNAi. These results indicate that the MAPK signal, along with the STAT3 signal, is essential for immune evasion by human melanomas that have constitutively active MAPK signaling and is a potential molecular target for overcoming melanoma cell evasion of the immune system.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

• Lin, J., Takata, M., Murata, H., Goto, Y., Kido, K., Ferrone, S., Saida, T. (2009). Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi. JNCI J Natl Cancer Inst 101: 1423-1427 [Abstract] [Full Text]  
• Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., Yu, H. (2009). Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy. Cancer Res. 69: 2497-2505 [Abstract] [Full Text]  
• Massoumi, R., Kuphal, S., Hellerbrand, C., Haas, B., Wild, P., Spruss, T., Pfeifer, A., Fassler, R., Bosserhoff, A. K. (2009). Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. JEM 206: 221-232 [Abstract] [Full Text]  
• Sheridan, C., Brumatti, G., Martin, S. J. (2008). Oncogenic B-RafV600E Inhibits Apoptosis and Promotes ERK-dependent Inactivation of Bad and Bim. J. Biol. Chem. 283: 22128-22135 [Abstract] [Full Text]  
• Marques, C. A., Hahnel, P. S., Wolfel, C., Thaler, S., Huber, C., Theobald, M., Schuler, M. (2008). An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression. Blood 111: 1413-1419 [Abstract] [Full Text]  
• Gajewski, T. F. (2007). Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment. Clin. Cancer Res. 13: 5256-5261 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS